NCT01401530View on ClinicalTrials.gov

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

January 31, 2016

Conditions
Peripheral T-Cell Lymphoma
Interventions
BIOLOGICAL

denileukin diftitox (E7777)

E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.

Trial Locations (4)

Unknown

Nagoya

Kashiwa

Isehara

Chuo-ku

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT01401530 - E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma | Biotech Hunter | Biotech Hunter